The Latest Cardiac and Vascular News
Data Demonstrate In Vivo Adenine Base Editing Can Turn Off Either PCSK9 or ANGPTL3 in the Liver and Substantially Lower LDL Cholesterol or Triglyceride Levels CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human primates that demonstrate the successful use of base […]
Proceeds Will Be Used to Progress Lead Program to Phase 1 Clinical Trials and Expand Pipeline Programs CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of physician and scientist Andrew Bellinger, M.D., Ph.D., as the company’s chief scientific officer. Dr. Bellinger joins Verve from […]
Dr. Geall Joins the Company’s World-class Scientific Advisors in Cardiology, Vaccine Development and Human Genetics CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of Andrew Geall, […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company, today announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve brings […]
